The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), preliminary antitumor ORIC-114 when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.
5 Primary · 6 Secondary · Reporting Duration: 36 months
42 Total Participants · 1 Treatment Group
Primary Treatment: Dose Escalation · No Placebo Group · Phase 1
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: